mp.weixin.qq.com·· 19 hours agoPickScore94
DeLLphi-305 Phase III: Tarlatamab plus Durvalumab First-Line Maintenance in ES-SCLC Cuts Death Risk 58%
In brief
The Phase III DeLLphi-305 trial showed that tarlatamab combined with durvalumab as first-line maintenance therapy for ES-SCLC extended median overall survival from 12.7 months to 21.1 months, a 58% reduction in the risk of death (HR 0.42; 95% CI 0.32-0.54; P<0.001).
Why it matters
The source provides OS, PFS, HR and safety data from a randomized control group, allowing direct comparison with durvalumab maintenance alone.
Source: mp.weixin.qq.com · mp.weixin.qq.com